Literature DB >> 2401718

Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity.

B Zumoff1, G W Strain, L K Miller, W Rosner, R Senie, D S Seres, R S Rosenfeld.   

Abstract

It is known that plasma total testosterone (T) is decreased in obese men in proportion to the degree of obesity, but similar information is not available for plasma free T and non-sex-hormone-binding globulin (SHBG)-bound T. We measured the 24-h mean plasma total T in 48 healthy (non-weight-stable men, aged 18-55 yr, with body mass indexes (BMI) ranging from 21-95 kg/m2. Free T and non-SHBG-bound T were calculated using the measured total T, the concentrations of albumin and SHBG, and the association constants of T to albumin and SHBG. Total body fat content was measured by deuterium-water isotope dilution. Findings were as follows. 1) BMI was very highly correlated with total body fat content (r = 0.96; P less than 0.001); thus, the degree of obesity can be calculated just as appropriately from simple height and weight measurements as from measurements of total body fat content. 2) Total, non-SHBG-bound, and free T were all highly correlated inversely with BMI; for total T, r = -0.727, P less than 0.01; for non-SHBG-bound T, r = 0.677, P less than 0.01; and for free T, r = -0.653, P less than 0.01. Thus, free T and non-SHBG-bound T are decreased in obese men in proportion to the degree of obesity, just as is the case for total T; percentage-wise, the decrease was the same for all 3 parameters.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401718     DOI: 10.1210/jcem-71-4-929

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  64 in total

Review 1.  The medical risks of obesity.

Authors:  F Xavier Pi-Sunyer
Journal:  Obes Surg       Date:  2002-04       Impact factor: 4.129

2.  A potential relationship between diffuse musculoskeletal pain and hypogonadism.

Authors:  Jaclyn K Anderson; Rebecca Tuetken; Valerie Hoffman
Journal:  BMJ Case Rep       Date:  2010-01-13

3.  Fatty acid metabolism in the elderly: effects of dehydroepiandrosterone and testosterone replacement in hormonally deficient men and women.

Authors:  Christina Koutsari; Asem H Ali; K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Sundeep Khosla; Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

Review 4.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

5.  Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men.

Authors:  Ahmad Hammoud; Mark Gibson; Steven C Hunt; Ted D Adams; Douglass T Carrell; Ronette L Kolotkin; A Wayne Meikle
Journal:  J Clin Endocrinol Metab       Date:  2009-01-27       Impact factor: 5.958

Review 6.  Implications of adiponectin in linking metabolism to testicular function.

Authors:  Luc J Martin
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  Age-related prevalence of low testosterone in men with spinal cord injury.

Authors:  William A Bauman; Michael F La Fountaine; Ann M Spungen
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

8.  Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study.

Authors:  D Simon; P Preziosi; E Barrett-Connor; M Roger; M Saint-Paul; K Nahoul; L Papoz
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

9.  Testosterone concentrations in diabetic and nondiabetic obese men.

Authors:  Sandeep Dhindsa; Michael G Miller; Cecilia L McWhirter; Donald E Mager; Husam Ghanim; Ajay Chaudhuri; Paresh Dandona
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.